45th week of 2009 patent applcation highlights part 28 |
Patent application number | Title | Published |
20090274606 | PROCESS FOR PRODUCTION OF SILICON TETRAFLUORIDE, AND APPARATUS FOR THE PROCESS - Disclosed is a process for production of silicon tetrafluoride which can reduce the cost for the silicon tetrafluoride production and can also reduce the quantities of waste products produced in the process. Also disclosed is an apparatus for use for the process. The method comprises the steps of: (a) a high-silica fluorosilicic acid production step in which a raw material ( | 2009-11-05 |
20090274607 | Method for purifying silicon - The present invention provides for methods of purifying silicon, methods for obtaining purified silicon, as well as methods for obtaining purified silicon crystals, purified granulized silicon and/or purified silicon ingots. | 2009-11-05 |
20090274608 | CALCIUM-SILICATE BASED SLAG FOR TREATMENT OF MOLTEN SILICON - A method for making solar grade silicon from metallurgical grade silicon is disclosed, which including, treating a calcium-silicate based slag by molten calcium-silicate based slag in a first vessel, whereby phosphorous in the calcium-silicate based slag is transferred to the ferrosilicon alloy producing a calcium-silicate based containing less than 3 ppmw phosphorous; obtaining the calcium-silicate based slag containing less than 3 ppmw phosphorous from the first vessel; treating a molten metallurgical grade silicon in a second vessel with the calcium-silicate based slag containing less than 3 ppmw phosphorous to reduce the content of phosphorous, boron and iron in the metallurgical grade silicon; and removing solar grade silicon with low content of phosphorous, boron and iron from the second vessel. | 2009-11-05 |
20090274609 | Synthesis Of High Quality Carbon Single-Walled Nanotubes - Methods and processes for synthesizing high quality carbon single-walled nanotubes (SWNTs) are provided. A carbon precursor gas at reduced concentration (pressure) is contacted with a catalyst deposited on a support and at temperature about 10° C. above the SWNT synthesis onset temperature, but below the thermal decomposition temperature of the carbon precursor gas for given growth conditions. The concentration (pressure) of the carbon precursor gas can be controlled by reducing the total pressure of the gas, or by diluting with an inert carrier gas, or both. The methods produce SWNTs with the ratio of G-band to D-band in Raman spectra (I | 2009-11-05 |
20090274610 | Method for growing carbon nanowalls - A method for growing carbon nanowalls on a base material is disclosed. The method comprises mixing a predetermined amount of a hydrocarbon gas with a predetermined amount of at least one non hydrocarbon gas; placing said base material in a reaction chamber having a first portion and a second portion, first portion is extended from a first end of reaction chamber to first end of base material; creating a radical in reaction chamber which comprises a hydrocarbon radical and a non hydrocarbon radical; applying the radical to the base material; and growing carbon nanowalls on said base material based on said hydrocarbon radical. | 2009-11-05 |
20090274611 | CARBON FIBROUS STRUCTURE - A method for forming a carbon fibrous structure having a granular part, to which a plurality of carbon fibers are bound, includes heating a mixture of a carbon source and a catalyst at a temperature between 800 and 1300° C. to produce a first intermediate, and heating the first intermediate to remove hydrocarbons, at a temperature between 800 and 1200° C. to produce a first product. The method further includes heating the first product at a temperature between 2400 and 3000° C. to produce a final product. The carbon source includes at least two compounds having different decomposition temperatures or a compound that can produce, when heated at a temperature between 800 and 1300° C., at least two components having different decomposition temperatures. The catalyst may include an iron-containing catalyst, which may be introduced into a reaction chamber in a gaseous state, without being deposited on a substrate. | 2009-11-05 |
20090274612 | PROCESS FOR PRODUCING SUPPORTED RUTHENIUM OXIDE AND PROCESS FOR PRODUCING CHLORINE - The present invention provides a process for producing supported ruthenium oxide comprising a step of supporting a ruthenium compound on a carrier and then calcining it in an oxygen-containing gas atmosphere, wherein the ruthenium compound has a total of each content of sodium, calcium, magnesium, iron, silicon, aluminum, copper and zinc of 500 weight ppm or less based on the amount of ruthenium. | 2009-11-05 |
20090274613 | Hydrogen Production Using Ammonia Borane - Hydrogen (“H | 2009-11-05 |
20090274614 | HYDROGEN STORAGE MATERIAL AND PREPARATION THEREOF - A hydrogen storage material comprises particles of a hydrogen storage alloy dispersed in a matrix. The alloy has a formula of LNi | 2009-11-05 |
20090274615 | Device for the Generation of Hydrogen Gas by Dehydrogenation of Hydrocarbon Fuels - A device for generation of hydrogen gas by dehydrogenation of hydrocarbon fuels. The device includes a fuel reservoir connected to a reactor by a fuel line to supply said reactor with fuel. The reactor has a first discharge for recycling of residual hydrocarbons generated during dehydrogenation to the fuel reservoir and optionally cooperates with a catalyst. The fuel reservoir may contact a heat exchanger by the fuel line and the first discharge. The fuel may be preheated by the heat exchanger which may be introduced to the reactor by the fuel line and the reactor may have a heating device for heating the introduced fuel to reaction temperature. The residual fuel generated by dehydrogenation in the reactor may be cooled by the heat exchanger and may be returned to the fuel reservoir. The reactor may have a second discharge for the extraction of the hydrogen gas generated on dehydrogenation. | 2009-11-05 |
20090274616 | ZEOLITE MEMBRANES FOR HYDROGEN GAS PRODUCTION AND METHOD OF PRODUCING HYDROGEN GAS USING THE ZEOLITE MEMBRANES - To provide a method for manufacturing zeolite membrane that has characteristics of being resistant to the reaction for a long time and in the high-temperature range, and has characteristic of long-duration hydrogen generation. The inventors of the present invention successfully produced a highly dense zeolite membrane by the steps of: evacuating the surface of porous support not adding the zeolite seed crystals dropwise, thus densely filling the seed crystals in the micropores; and applying hydrothermal treatment to the seed crystals. In addition, the inventors of the present invention confirmed that the zeolite membrane manufactured by the above methods has the characteristic of generating hydrogen for a long time. | 2009-11-05 |
20090274617 | Adsorbent - An absorbent of ZSM-5 zeolite ion-exchanged with copper ion, characterized in that at least 60% or more of the copper sites in the copper ion-exchanged ZSM-5 zeolite are copper (I) sites and preferably at least 70% or more of the copper (I) sites are three-oxygen-coordinated copper (I) sites. | 2009-11-05 |
20090274618 | TADG-15: an extracellular serine protease overexpressed in carcinomas - The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer. | 2009-11-05 |
20090274619 | TUMOR VASCULATURE MARKERS AND METHODS OF USE THEROF - This invention provides methods of detecting and localizing tumor vasculature cells (TVC) and solid tumors; and treating, impeding vascularization of, and determining the stage of solid tumors in a subject, comprising the step of contacting a subject or a TVC with a ligand that binds to a nucleic acid molecule of the present invention, or binds to a protein encoded by the nucleic acid molecule. | 2009-11-05 |
20090274620 | Hybridoma Cell Line G250 and its use for Producing Monoclonal Antibodies - This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies | 2009-11-05 |
20090274621 | USE OF PYRENE TO CARRY NON-PEPTIDE AGENTS ACROSS THE BLOOD BRAIN BARRIER - Described are methods for delivering a non-peptide agent across the blood-brain barrier, comprising administering to a subject a conjugate comprising (i) a non-peptide agent and (ii) pyrene, and related detection and therapeutic method. | 2009-11-05 |
20090274622 | NECROSIS AVID TRACER AGENT - The invention relates to a method for obtaining an image of ischemic, infarcted or necrotic tissue in a subject, comprising the step of administering an imaging agent comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound. For example, the invention concerns to the use of phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives, and more specifically hypericin or its derivatives, as necrosis or infarct specific agents. The phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives can be labeled with a radionuclide, a radiopaque material or a material enhancing the effects magnetic resonance imaging. The invention further features a pharmaceutical composition comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound optionally conjugated to a radionuclide or a radiopaque material, provided that said phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound is not mono-[ | 2009-11-05 |
20090274623 | IN VIVO IMAGING AGENTS FOR MET RECEPTOR TYROSINE KINASE - Provided are in vivo imaging agents comprising muteins of hTLc having detectable binding affinity for c-Met or a domain thereof, coupled to a signal generator, and the mutein coupled to a signal generator is disposed in a pharmaceutically acceptable carrier. Also provided are diagnostic methods using in vivo imaging agents comprising muteins of hTLc having detectable binding affinity for c-Met or a domain thereof. | 2009-11-05 |
20090274624 | RADIOTRACERS FOR IMAGING P-GLYCOPROTEIN FUNCTION - P-glycoprotein transporter (P-gp) acts as a pump at the blood-brain barrier to exclude a wide range of xenobiotics (e.g., toxins, drugs, etc.) from the brain and is also expressed in a tumor in response to exposure to established or prospective chemotherapeutics (a phenomenon known as multidrug resistance). This invention concerns the preparation and use of radiotracers for imaging P-gp function in vitro and in vivo. Radiotracers of the present invention are avid substrates for P-gp and have structures based on N-Desmethyl-loperamide. | 2009-11-05 |
20090274625 | Compositions and Methods for The Treatment of Cancer - The instant invention provides methods and compositions for the treatment and diagnosis of cancer, e.g., cancers characterized by the expression of prostate specific membrane antigen (PSMA). | 2009-11-05 |
20090274626 | TARGETING TNF-alpha CONVERTING ENZYME(TACE)- DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY - The invention provides methods for modulating tumor cell proliferation by contacting cells (e.g. tumor cells) with a TACE inhibitor and a compound that inhibits EGFR tyrosine kinase, whereby the TACE inhibitor enhances the sensitivity of the cell to the EGFR tyrosine kinase inhibitor. Additionally, methods for treating cancer and methods for identifying TACE inhibitors is also provided. | 2009-11-05 |
20090274627 | Composition for Regeneration of Periodontal Soft Tissue and Method for Producing the Same - It is intended to provide a composition for regeneration of periodontal soft tissue less invasively and a method for producing the composition. The composition for regeneration of periodontal soft tissue is prepared so as to contain a cell selected from an undifferentiated/stem cell or a blast cell having an ability to form gingiva, a matrix material and blood platelet plasma. With the composition, free gingiva as well as attached gingiva can be regenerated less invasively with an effective and good aesthetics. | 2009-11-05 |
20090274628 | RECONSTITUTABLE MICROSPHERE COMPOSITIONS USEFUL AS ULTRASONIC CONTRAST AGENTS - Methods and suspensions are provided that are useful for preparing readily reconstitutable, dry compositions of micro- or nanospheres. The dry compositions find use in diagnostic applications such as ultrasonic imaging. The suspension includes as key ingredients one or both of t-butyl alcohol and/or an amorphous sugar (or mixture of amorphous sugars) in specified amounts that reduce aggregation of the particles comprising the suspension. | 2009-11-05 |
20090274629 | Sanitizing Composition and Method of Preparation - The invention provides a sanitizing composition in the form of a viscous liquid or gel suitable for use as a handwash composition comprising alcohol, water and a thickener wherein the viscous liquid or gel has particles suspended therein, wherein said particles provide the composition with a granular texture and are capable of being worn away when rubbed. The particles may deliver one or more agents to the skin e.g. antimicrobial, antibacterial or antiviral agents, emollients and/or moisturizers, fragrances, colourings or UV markers. | 2009-11-05 |
20090274630 | RED BLOOD CELL-DERIVED VESICLES AS A NANOPARTICLE DRUG DELIVERY SYSTEM - Red blood cell-derived vesicles (RDV) as a nanoparticle drug delivery system. The RDV are smaller than one micrometer, capable of encapsulating and delivering an exogenous substance into cells. The substance may be at least one selected from the group consisting of fluorophores, nucleic acids, superparamagnetic compounds and therapeutic agents. The RDV are capable of delivering encapsulated substances into cells including stem cells. The delivered substance within the cell or stem cell may be traced or tracked using a suitable device either in vitro or in vivo. | 2009-11-05 |
20090274631 | RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions - RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy. | 2009-11-05 |
20090274632 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof - The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof as bitter taste blockers or flavor modulators in, e.g., coffee and coffee flavored foods, beverages and medicaments. Also, the present invention relates to the discovery of a compound that antagonizes numerous different human T2Rs and the use thereof in assays and as a bitter taste blocker in compositions for ingestion by humans and animals. | 2009-11-05 |
20090274633 | TOOTH POWDER CONTAINING ELVAN AS RADIATION SOURCE OF FAR INFRARED RAY - The present invention relates to tooth powder containing elvan as a radiation source of a far infrared ray wherein the tooth powder includes 10 weight % to 90 weight % of elvan as a radiation source of a far infrared ray and 10 weight % to 90 weight % of bamboo salt, and is characterized in that the rate of the elvan and the bamboo salt is 10:90 to 90:10. Also, it is of sovereign remedy in preventing teeth from decaying with medicine made by desiccating sap of a lacquer tree. | 2009-11-05 |
20090274634 | Novel crosslinked polymeric substrates methods of preparation and end use applications of the substrates - A composition of matter wherein the composition comprises a siliceous substrate having silanols on the surface and a polymer selected from the group consisting essentially of a water soluble polymer, a water soluble copolymer, an alcohol soluble polymer, an alcohol soluble copolymer, and combinations of such polymers, wherein the polymer is chemically bonded to the siliceous substrate by a silane linking material having the general formula | 2009-11-05 |
20090274635 | Bactericide having selectivity to cariogenic bacterium, and a method for sterilization of cariogenic bacterium - The bacteriolytic effect of a bacterial cell wall lytic enzyme can be increased by the addition of a surfactant to the enzyme. As a result, the time required for lysis of cariogenic bacterium with the bacterial cell wall lytic enzyme can be shortened, and the practical utility of the bacterial cell wall lytic enzyme (such as automutanolysin) as a prophylactic or therapeutic agent for dental caries can be improved. | 2009-11-05 |
20090274636 | TOOTH ENAMEL DISSOLUTION INHIBITOR - An object of the present invention is to provide a tooth enamel dissolution (decalcification) inhibitor that can inhibit the dissolution of tooth enamel to keep teeth healthy. | 2009-11-05 |
20090274637 | Depigmenting or Brigthening Cosmetic Composition at Least One Oxazolin as an Active Ingredient - The invention relates to the cosmetic use of at least one oxazolin as a depigmenting active ingredient in a depigmenting composition, and to the associated cosmetic treatment method. The invention also relates to the use of at least one oxazolin for preparing an active medicament as a depigmenting agent, and to a depigmenting cosmetic composition comprising at least one oxazolin as a depigmenting active ingredient. | 2009-11-05 |
20090274638 | COSMETIC USE OF A C-GLYCOSIDE DERIVATIVE IN COMBINATION WITH ASCORBIC ACID - The present invention relates to a cosmetic use of a synergistic combination of at least one C-glycoside derivative with at least ascorbic acid, or one of its derivatives or analogs, for preventively or curatively treating the signs of aging of body or facial skin, irrespective of whether they are chronobiological or photoinduced. | 2009-11-05 |
20090274639 | COMPOSITION FOR HAIR - It is an object of the present invention to provide a composition for hair which comprises a hydrophobic ingredient although it has an extremely low alcohol concentration, and which has a low viscosity. The present invention provides a composition for hair having a viscosity of 30 P or less, which comprises 1% to 50% by weight of alcohol and which further comprises a hydrophobic hair active ingredient. | 2009-11-05 |
20090274640 | Hair Care Compositions - Hair care compositions are disclosed which comprise a silicone polyurethane polymer, an ester, and a fluorosilicone. The compositions are useful for improving color retention of artificially colored hair. | 2009-11-05 |
20090274641 | COSMETIC COMPOSITION COMPRISING ONE OR MORE VINYLFORMAMIDE/VINYLFORMAMINE COPOLYMERS AND ONE OR MORE THICKENING POLYMERS - A cosmetic composition. In a cosmetically acceptable medium:
| 2009-11-05 |
20090274642 | Hair Care Compositions for Preventing Oxidative Damage to Hair, Methods of Use, and Methods of Marketing Such Compositions - Hair care compositions, methods, and methods of marketing that can prevent oxidative damage to hair. Such compositions comprise a follicular fungi reduction agent (“FFRA”) and can be applied to any areas where the appearance of less oxidative damage is desired, such as the scalp or face. The present invention also relates to methods of using and marketing such compositions. | 2009-11-05 |
20090274643 | Low viscosity, high molecular weight linear random-block silicone polyalkyleneoxide copolymers - The present invention describes novel non-hydrolyzable, linear, random block copolymers comprising units of polysiloxanes and polyalkyleneoxides linked by bis-aminofunctional groups. These copolymers have been successfully applied as textile enhancers as well as conditioning agents for hair and skin care products. | 2009-11-05 |
20090274644 | Ant Eradication Composition and Method - A composition and method for eradicating ants is provided wherein the composition includes borax, sugar and yeast. The messenger ants taste the composition; the workers take the composition back to the Queen who also eats the composition. The composition renders her infertile, and later distends the gastrointestinal tract. | 2009-11-05 |
20090274645 | GALL MIDGE PHEROMONE MIXTURE - The present invention relates to a pheromone composition for attracting male Hessian fly, | 2009-11-05 |
20090274646 | Methods for Controlling Molluscs - Novel materials for controlling molluscs, such as snails and slugs, using carbohydrates including celluloses, hemicellulose complexes, and/or lignin, for inducing death in molluscs. The materials are non-toxic, will not contaminate a drinking water supply, will not harm fish, birds or wild life, will not cause any harmful effects if swallowed or absorbed through the skin, will not harm children or pets, and can be safely eaten by domestic animals and livestock that may consume such dead molluscs. The materials may be applied in various formulations at various water contents. The materials do not provide nutrition to the molluscs, and disrupt normal bodily functions resulting in death. An attractant may be included to encourage ingestion by the molluscs. | 2009-11-05 |
20090274647 | Immunotherapeutic Formulations with Interleukin-2-Neutralizing Capacity - The present invention is related to pharmaceutical compositions based on vaccines and monoclonal antibodies that neutralize the Interleukin-2, which are useful in the treatment of tumors. | 2009-11-05 |
20090274648 | HEPATITIS C VIRUS INHIBITORS - Hepatitis C virus inhibitors having the general formula | 2009-11-05 |
20090274649 | Bispecific Antibody Point Mutations for Enhancing Rate of Clearance - A mutant bispecific antibody that includes (a) a human hinge constant region from IgG having one or more amino acid mutations in the C | 2009-11-05 |
20090274650 | INHIBITORS OF ASPARTYL PROTEASE - The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity. | 2009-11-05 |
20090274651 | Therapeutic agent for infections, and treatment method using the same - (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.
| 2009-11-05 |
20090274652 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 2009-11-05 |
20090274653 | INTERLEUKIN-2 MUTANTS WITH REDUCED TOXICITY - Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a wildytpe form of the mutant IL-2 while retaining many of the immune activating properties of IL-2. Invention IL-2 mutants can be used to stimulate the immune system of an animal and may be used in the treatment of various disorders and conditions. | 2009-11-05 |
20090274654 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 2009-11-05 |
20090274655 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS - Anti-viral agents of compounds of Formula (I): wherein A, R | 2009-11-05 |
20090274656 | HEPATITIS C VIRUS INHIBITORS - Hepatitis C virus inhibitors are disclosed having the general formula: | 2009-11-05 |
20090274657 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2009-11-05 |
20090274658 | Tight Junction Modulating Peptides for Enhanced Mucosal Delivery of Therapeutic Compounds - Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject, in which the permeabilizing peptide is a tight junction modulating peptide (TJMP), a TJMP analogue, a conjugate of a TJMP, a conjugate of a TJMP analogue, or complexes thereof. The permeabilizing agent reversibly enhances mucosal epithelial paracellular transport, typically by modulating epithelial junctional structure and/or physiology at a mucosal epithelial surface in the subject. | 2009-11-05 |
20090274659 | Compositions And Methods For Producing Fermentation Products And Residuals - The present invention provides compositions and methods designed to increase value output of a fermentation reaction. In particular, the present invention provides a business method of increasing value output of a fermentation plant. The present invention also provides a modified fermentation residual of higher commercial value. Also provided in the present invention are complete animal feeds, nutritional supplements comprising the subject ferment residuals. Further provided by the present invention is a method of performing fermentation, a modified fermentative microorganism and a genetic vehicle for modifying such microoganism. | 2009-11-05 |
20090274660 | PLURIPOTENT THERAPEUTIC COMPOSITIONS AND USES THEREOF - Synthetic Stem Cell-like Tissue Healing and Regeneration Medication with Anti-inflammatory, Protein Synthesis, Enzyme Deficiency Activation and Genetic Therapy, and Anti-cancer Agent derived from a series of inventions that include these products of Biomolecular Engineering, Drug Discovery from a Biologic Periodic Table of Applied Biochemistry and Biophysics. Tissue has a self healing effect promoting tissue healing and tissue regeneration. Not only does it maintain good health but also it has been observed that the patient's blood is withdrawn from the patient and applied to the ulcer has healing qualities. Cartilage placed in a wound promotes and accelerates wound healing. The anabolic biochemical and biophysical equivalent of tissue has been found in these embodiments to have the same pharmacologic qualities, when devoid of genetic DNA mismatch and other catabolic factors including the catabolic effects of microorganism overgrowth that lacks pro-biotic qualities. The healing efficacy of these tissue components gives us further appreciation of the protective action of human tissue over and above and other than the immune protective system or perhaps an integral component part of the immune system. | 2009-11-05 |
20090274661 | USE OF BIFIDOBACTERIUM LONGUM FOR THE PREVENTION AND TREATMENT OF INFLAMMATION - The invention relates to the use, in the manufacture of a medicament or a therapeutic nutritional composition for preventing or reducing inflammation in a mammal, of | 2009-11-05 |
20090274662 | Methods And Kits For The Treatment Of Inflammatory Bowel Disorder Conditions - The present invention comprises methods and kits that are useful for the treatment an inflammatory bowel disease. The methods comprise administering to a mammal in need of treatment a composition comprising an active agent in combination with a probiotic and/or optionally an antibiotic. | 2009-11-05 |
20090274663 | Materials and Methods Relating to Cell Based Therapies - The invention provides a novel multipotent cell population of adult origin that can be used to treat ageing and disease, particularly by transplantation to site of cellular damage. | 2009-11-05 |
20090274664 | Method of culturing vascular smooth muscle cells, culture device and medical material obtained by the culture - There is provided a method for culturing vascular smooth muscle cells while maintaining their normal function, and a culture device and regenerative medical material for the same. The method takes advantage of vascular smooth muscle cell recognition of elastin as an extracellular matrix. The invention provides a method for culturing vascular smooth muscle cells on elastin, a culture device having elastin anchored on the cell-growing surface, a culture device wherein the cell-growing surface is composed of an elastin molded article, and medical materials obtained by culturing vascular smooth muscle cells using such culture devices. | 2009-11-05 |
20090274665 | Stem Cells For Treating Lung Diseases - The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow. | 2009-11-05 |
20090274666 | B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE - The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors Also included are methods of making and using these co-stimulatory polypeptides. | 2009-11-05 |
20090274667 | RETINAL PIGMENT EPITHELIAL STEM CELLS - The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment. | 2009-11-05 |
20090274668 | Combined Regulation of Neural Cell Production - This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells. | 2009-11-05 |
20090274669 | Dendritic Cells Transiently Transfected with a Membrane Homing Polypeptide and their use - The invention provides improved methods of producing dendritic cells (“DCs”) that transiently express a membrane homing peptide and optionally at least one additional antigen. These DCs have the ability to home to lymph nodes in vivo. In some embodiments, these DCs can be administered to a patient intravenously and can subsequently home to lymph nodes and stimulate an immune response. The methods and DCs of the invention are useful for the treatment of various diseases and disorders. | 2009-11-05 |
20090274670 | DPH2 GENE DELETION MUTANT AND USES THEREOF - Diphtheria and | 2009-11-05 |
20090274671 | VECTOR ENCODING HUMAN GLOBIN GENE AND USE THEREOF IN TREATMENT OF HEMOGLOBINOPATHIES - Recombinant lentiviral vectors having a region encoding a functional β-globin gene; and large portions of the β-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of β-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies, including β-thalessemia and sickle-cell disease. For example, hematopoietic progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the returned population. For example, a selection marker which makes transformed cells more drug resistant than untransformed cells allows selection by treatment of the cells with the corresponding drug. | 2009-11-05 |
20090274672 | Lactobacillus Isolates Having Anti-Inflammatory Activities and Uses of the Same - Disclosed herein are two | 2009-11-05 |
20090274673 | COMPOSITION FOR TOPICAL TREATMENT OF ACNE - The composition described is to be applied topically to the skin to treat acne and other skin disorders caused in part or wholly by bacterial or mycosal infections. Acne and related skin disorders have complex causes. This formula contains compounds, including an effective amount | 2009-11-05 |
20090274674 | Heterocyclic Oxime Compounds, Process for Their Preparation and Pharmaceutical Compositions Containing Them - Compounds of formula (I): | 2009-11-05 |
20090274675 | Migraine tonic - This invention is proposing a combination of a system of migraine headache remedies from non-prescription pharmaceuticals in the form of an aqueous drinkable tonic utilizing as the component foundation the main ingredient Ubiquinone (Co-enzyme-Q10) coupled with one or more of the following non-prescription natural or synthesized pharmaceuticals to include but are not inclusive of Tanacetum Parthenium, or Hypericin and/or Hyperforin, Petasin, Magnesium Citrate, and Riboflavin, the selection of which is determined upon the user and the user's other medications. | 2009-11-05 |
20090274676 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A PDE-4 INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a phosphodiesterase-4 inhibitor for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. | 2009-11-05 |
20090274677 | ANTIOXIDANT FOR USE IN COSMETIC, MEDICATED AND PHARMACEUTICAL PREPARATIONS - The invention provides the use a 2,2-dimethyl chroman as a SOD mimetic in a cosmetic preparation. Cosmetic preparations comprising a 2,2-dimethyl chroman as a SOD mimetic are described, as well as methods for treating or preventing free radical damage to skin cells and treating or preventing hair loss which comprise topical administration of a 2,2-dimethyl chroman as a SOD mimetic. | 2009-11-05 |
20090274679 | PRODUCTION AND USE OF HUMAN BUTYRYLCHOLINESTERASE - The present invention concerns the production of human butyrylcholinesterase (BuChE) in transgenic plants and use of the derived BuChE as effective countermeasures against toxic agents such as pesticides, toxins, certain drugs and non-conventional warfare agents, as well as treatments for diseases and conditions associated with depressed cholinesterase levels. | 2009-11-05 |
20090274680 | Human Phospholipases - The invention provides human lipid metabolism enzymes (LME) and polynucleotides which identify and encode LME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LME. | 2009-11-05 |
20090274681 | NOVEL GENE ENCODING A DNA REPAIR ENZYME AND METHODS OF USE THEREOF - An isolated nucleic acid molecule encoding a human DNA repair enzyme, MED1, is disclosed. Like other mismatch repair genes which are mutated in certain cancers, MED1, encoding nucleic acids, proteins and antibodies thereto may be used to advantage in genetic or cancer screening assays. MED1, which recognizes and cleaves DNA, may also be used for the diagnostic detection of mutations and genetic variants. | 2009-11-05 |
20090274682 | DEMETHYLATION AND INACTIVATION OF PROTEIN PHOSPHATASE 2A - Embodiments of the present invention relate to atomic coordinates for PME-1 alone or in complex with PP2A, as well as methods for using these atomic coordinates to prepare inhibitors of PME-1 and/or PP2A and inhibitors prepared using such methods. Further embodiments relate to biochemical analyses of the interactions of PME-1 alone or in complex with PP2A. Further embodiments relate to compositions including mimetics and small molecules, optionally, secondary agents, which may be used to treat disorders in which PME-1 and/or PP2A activity plays a contributing role. | 2009-11-05 |
20090274683 | ADAMTS13 GENES AND PROTEINS AND VARIANTS, AND THERAPEUTIC COMPOSITIONS AND METHODS OF UTILIZING THE SAME - The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13. | 2009-11-05 |
20090274684 | Methods for the Identification of Modulators of OSGPR114 or OSGPR78 Activity, and their use in the Treatment of Disease - This invention relates to the identification of LPA as a ligand for the G-protein coupled receptors OSGPR 114 and OSGPR78. The invention is directed to new methods for screening candidate drugs for their ability to modulate the activity of OSGPR114 or OSGPR78, and new pharmaceutical agents identified by these methods. It is also directed to the use of such agents in the manufacture of medicaments for the treatment of OSGPR114 or OSGPR78 mediated diseases, and methods of treating diseases such as cancers by administering to an individual a therapeutic amount of a modulator of OSGPR114 or OSGPR78 identified by these methods. | 2009-11-05 |
20090274685 | ILT3 POLYPEPTIDES AND USES THEREOF - This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject. | 2009-11-05 |
20090274686 | NUCLEOSIDE PHOSPHONATE DERIVATIVES - The present invention discloses compounds of formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2009-11-05 |
20090274687 | ATTENUATION OF HYPOXIA INDUCED CARDIOVASCULAR DISORDERS - Blockade of stromal derived factor-1 (SDF-1), a stem cell mobilizer and/or its receptor, chemokine receptor 4 (CXCR4) attenuates and reverses hypoxia-induced cardiopulmonary remodeling in vivo. Compositions for treating hypoxia-induced cardiovascular disorders modulate the SDF-1/CXCR4 axis. | 2009-11-05 |
20090274688 | Antibodies to OPGL - Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described. | 2009-11-05 |
20090274689 | Co-Administration of a Thrombolytic and an Anti-CD18 Antibody in Stroke - A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction. | 2009-11-05 |
20090274690 | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system - Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca | 2009-11-05 |
20090274691 | Use of CD25 binding molecules in steroid-resistant patients - A method is provided for treating the diseases autoimmune hepatitis, eczema, vasculitis, temporal arteritis, sarcoid and Crohn's disease, in a steroid-resistant or steroid-sensitive patient. The method comprises administering to the patient an effective amount of a CD25 binding molecule and a steroid. | 2009-11-05 |
20090274692 | CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF - The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases. | 2009-11-05 |
20090274693 | Method of Treating Cancer using a cMet and AXL Inhibitor and an ErbB Inhibitor - The present invention relates to a method of treating cancer in a patient comprising administering to the patient therapeutically effective amounts of: | 2009-11-05 |
20090274694 | CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto. | 2009-11-05 |
20090274695 | Inhibition of urokinase-type plasminogen activator (uPA) activity - The invention concerns methods for inhibiting the binding of urokinase-type plasminogen activator (uPA) to its receptor uPAR and/or inhibiting uPA biological activity. The invention further concerns methods for inhibiting tumor formation or metastasis, angiogenesis, such as tumor angiogenesis, and screening assays for identifying CYTL1 agonists. | 2009-11-05 |
20090274696 | METHODS FOR TREATING INFLAMMATION - Provided are methods and compositions for reducing airway hyperresponsiveness and other inflammatory diseases, disorders and conditions in a mammal by decreasing FIZZ1 (Found in Inflammatory Zone 1) activity. Also provided are methods and compositions for identifying modulators of airway inflammation and/or inhibitors of FIZZ1. The present invention encompasses modulators of airway inflammation and/or inhibitors of FIZZ1 and uses thereof. In addition, the present invention provides methods and compositions for enhancing an immune response based on FIZZ1 protein. | 2009-11-05 |
20090274697 | Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen - This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-α (FR-α). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-α”), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments. | 2009-11-05 |
20090274698 | Combination anti-cancer therapy - The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. Examples of such anti-cancer agents or treatments include doxorubicin, cisplatin, or ionizing radiation. The present invention also provides a pharmaceutical composition comprising an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of the anti-cancer agent melphalan or 5-FU, and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. | 2009-11-05 |
20090274699 | UL16 BINDING PROTEIN 4 - ULBP4, a novel member of the ULBP family has been isolated and characterized. ULBP4 is a useful activator of immune effector cells, particularly of NK cells. | 2009-11-05 |
20090274700 | IL-31 RECEPTOR ANTIBODIES - Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 2009-11-05 |
20090274701 | CHLAMYDIA PNEUMONIAE POLYNUCLEOTIDES AND USES THEREOF - The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of | 2009-11-05 |
20090274702 | Method of treatment and Agents useful for same - The present invention relates generally to a method for the treatment and prophylaxis of inflammatory conditions. The present invention is predicated in part on the identification of cells of the monocyte/macrophage lineage being critical for inflammation and, in particular, chronic inflammation. In accordance with the present invention, it is proposed that the reduction in levels of monocyte/macrophage-type cells and/or a reduction in the production of inflammatory and pro-inflammatory mediators by these cells, especially locally, is effective in reducing inflammatory conditions. The present invention further provides animal models useful for screening for reducing levels of monocyte/macrophage-type cells and/or reducing the production of inflammatory and pro-inflammatory mediators of these cells. | 2009-11-05 |
20090274703 | Methods of treating inflammation using IL-17 antagonists - Aspects of the present invention provide methods for treating diseases associated with IL-17 mediated inflammatory or immunoregulatory reactions. | 2009-11-05 |
20090274704 | Anti-staphylococcus aureus antibodies - A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody is enriched for immunoglobulins having both an antigen-binding portion that binds a | 2009-11-05 |
20090274705 | IL-13 BINDING AGENTS - Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed. | 2009-11-05 |
20090274706 | ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR - The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies. | 2009-11-05 |